

## Conversation ID: 6064088db0200b32f3f3e848047c5ab6

we believe that KORSUVA has the potential to address pruritus across a range of medical conditions

at week 12 with respect to the weekly mean of the daily worst itching intensity score

during the second quarter of this year. So as you can see, we have a busy execution year ahead of us with numerous pruritus trials already ongoing

later this year. I'm kind of wondering what the gating steps are to getting that started? And if you could provide any additional color on the size or scope of that study?

we do have breakthrough therapy designation for this indication. We will be talking to the agency as we develop a bigger safety database,

So early second quarter. I think Derek made that in the comments is when we expect to complete enrollment, and then we'll read out the trial

Now turning onto our financial expectations. Based on timing expectations and projected costs of our clinical development plan, we expect that our current cash, cash equivalents and marketable securities

for their continued hard work to support the progress of our various programs, our investigators and most importantly,

will be sufficient to fund our operating expenses and capital expenditure requirements

And when you consider the regulatory strategy, is that -- is

This may seem like a silly question, but I'm kind of wondering what you think is